Last reviewed · How we verify
Infusion of remimazolam
At a glance
| Generic name | Infusion of remimazolam |
|---|---|
| Also known as | Continuous infusion of Byfavo |
| Sponsor | Korea University Guro Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Remimazolam and Propofol on Postoperative Delirium (NA)
- Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures (NA)
- Effect of Remimazolam on Postoperative Delirium (NA)
- Remimazolam Consumption: TCI vs. Manual Infusion (NA)
- A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined With Alfentanil for Anesthesia in Thoracic Surgery (PHASE4)
- The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial. (NA)
- Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients (PHASE4)
- Ideal Dosage for Sedation of Obese Patients Undergoing Knee or Hip Arthroplasty Under Spinal Anesthesia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infusion of remimazolam CI brief — competitive landscape report
- Infusion of remimazolam updates RSS · CI watch RSS
- Korea University Guro Hospital portfolio CI